Randomized Double-Blind Placebo-Controlled Proof of Concept Study to

Recruiting

99 years or below

All

Phase 2

10 participants needed

1 Location

Brief description of study

The objectives of the study are to assess the safety and efficacy of elezanumab in subjects with acute traumatic cervical SCI. The primary endpoint is the Upper Extremity Motor Score (UEMS), a subscore of the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI, 2019 criteria) during the treatment period. The primary analysis will be the comparison of a model-based area under the curve (AUC) of the UEMS scores between treatment and placebo. The secondary endpoints are the Spinal Cord Independence Measures (SCIM III) self-care score, and the change in UEMS from Baseline.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Medical Research
Age: 99 years or below
Gender: All

Updated on 09 Feb 2022. Study ID: 844979

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Randomized Double-Blind Placebo-Controlled Proof of Concept Study to Assess the Safety and Efficacy of Elezanumab in Acute Traumatic Cervical Spinal Cord Injury

Brief description of study

Eligibility of study

Find a site

Interested in the study